According to a market report by Lucintel, the future of the global metastatic colorectal cancer market looks promising with opportunities in the hospitals, cancer centers, ambulatory surgical centers, and others markets. The global metastatic colorectal cancer market is expected to reach an estimated $12 billion by 2031 from $9 billion in 2025 at a CAGR of 4% from 2025 to 2031. The major drivers for this market are growing advancement in treatment therapies, increasing awareness around early detection of cancer, and rising incidence of colorectal cancer.
A more
than 150-page report to understand trends, opportunity and forecast in global metastatic
colorectal cancer market to metastatic colorectal cancer by treatment
(chemotherapy, targeted therapies, immunotherapies, monotherapy &
combination therapy, and others), drug class (anti-egfr inhibitors, anti-vegf
therapies, anti-her2 therapies, immune checkpoint inhibitors, and others), end
use (hospitals, cancer centers, ambulatory surgical centers, and others), and
region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that, within the treatment category, chemotherapy will remain the
largest segment over the forecast period.
Within the
end use category, anti-vegf therapies will remain the largest segment.
Download
sample by clicking on metastatic
colorectal cancer market.
In terms
of region, North America will remain the largest region over the forecast
period.
Amgen, Eli
Lilly, Pfizer, Roche Holding AG, Merck Sharp & Dohme, Sanofi, Taiho
Oncology, Bristol Myers Squibb, Bayer, Novartis are the major suppliers in the metastatic colorectal cancer market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Needle-Free IV Connector Market
Wire-to-Board Connector Market
No comments:
Post a Comment